title: Bone loss and the evolving role of bisphosphonate therapy in prostate cancer.
abstract: Androgen deprivation therapy (ADT) can result in significant loss of bone mineral density (BMD) but to date, there are no prospective studies that document the true severity of bone loss and resulting fracture rates. In the general population, however, the incidence of low BMD is increasing in elderly men. Men suffer more morbidity and mortality from fractures associated with low BMD than women. Problems of underdiagnosis and undertreatment in men can be addressed with enhanced awareness of the risk factors for bone loss in men and the available treatment options. Guidelines for diagnosis of low BMD in women can probably be applied to men. Treatment options have not been studied as extensively in men. For men treated with ADT for prostate cancer, however, use of intravenous zoledronic acid at the initiation of ADT has been shown to prevent and even reverse bone loss. Although the routine use of bisphosphonates to prevent bone loss is not yet recommended, zoledronic acid is a logical choice of therapy in men who have low BMD at baseline or who develop bone loss during the course of therapy. In addition to its effects on BMD, zoledronic acid has also been shown to decrease skeletal morbidity in men with metastatic hormone-refractory prostate cancer. Whether zoledronic acid or other bisphosphonates might actually prevent or delay the development of bone metastases remains to be studied in randomized clinical trials.
authors.affiliation: Departments of Medicine and Urology, University of Washington School of Medicine, Seattle, WA 98109, USA. thigano@u.washington.edu
authors.forename: Celestia S
authors.initials: CS
authors.lastname: Higano
mesh_terms: D000367:Age Factors; D000726:Androgen Antagonists / Q000009:adverse effects; D015519:Bone Density; D001842:Bone and Bones / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000150:complications / Q000628:therapy*; D000077211:Zoledronic Acid
chemical_list: D000726:Androgen Antagonists; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid